Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano, Hiroto; Tian, Yu Shi; Hatabu, Asuka; Takagi, Tatsuya; Ueda, Mikiko; Ikeda, Kenji

doi:https://doi.org/10.1038/s41598-023-44142-2

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

Asano, Hiroto; Tian, Yu Shi; Hatabu, Asuka et al.

Scientific Reports, 2023, 13(1), 19272

アクセス数:901件（2025-08-15 07:41 集計）

固定URL: https://hdl.handle.net/11094/93232

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
SciRep_13_1_19272	pdf	なし	970 KB	149	2023.12.05

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
著者	著者名 Asano, Hiroto
	NRID 1000060761252 1000060761252 ORCID 0000-0002-8988-9453 0000-0002-8988-9453 researchmap permalink yushi-tian yushi-tian Scopus Author ID 55480219500 55480219500 著者名 Tian, Yu Shi
	NRID 1000040790895 1000040790895 researchmap permalink hata_06 hata_06 Scopus Author ID 55634731300 55634731300 著者名 Hatabu, Asuka
	NRID 1000080144517 1000080144517 ORCID 0000-0002-0044-0722 0000-0002-0044-0722 researchmap permalink ttakagi0530 ttakagi0530 Scopus Author ID 7403554415 7403554415 著者名 Takagi, Tatsuya
	NRID 1000090587966 1000090587966 researchmap permalink m61_iryouyaku m61_iryouyaku Scopus Author ID 35448391800 35448391800 著者名 Ueda, Mikiko
	NRID 1000010434812 1000010434812 researchmap permalink kenjiikeda kenjiikeda 著者名 Ikeda, Kenji
内容	Asano H., Tian Y.S., Hatabu A., et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports 13, 19272 (2023); https://doi.org/10.1038/s41598-023-44142-2.
抄録	Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.
出版者	Nature Research
収録物名	Scientific Reports
巻(号)	13(1)
ページ	19272
刊行年月	2023-11-06
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93232
eISSN	20452322
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1038/s41598-023-44142-2
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Scientific Reports. 2023, 13(1), p. 19272
DC.title	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
DC.creator	Asano, Hiroto
	Tian, Yu Shi
	Hatabu, Asuka
	Takagi, Tatsuya
	Ueda, Mikiko
	Ikeda, Kenji
DC.publisher	Nature Research
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2023-11-06
DC.identifier	https://doi.org/10.1038/s41598-023-44142-2
DC.description	Asano H., Tian Y.S., Hatabu A., et al. Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system. Scientific Reports 13, 19272 (2023); https://doi.org/10.1038/s41598-023-44142-2.
DCTERMS.abstract	Monoamine oxidase B (MAO-B) inhibitors are used to control Parkinson’s disease (PD). Selegiline, rasagiline, and safinamide are widely used as MAO-B inhibitors worldwide. Although these drugs inhibit MAO-B, there are pharmacological and chemical differences, such as the inhibitory activity, the non-dopaminergic properties in safinamide, and the amphetamine-like structure in selegiline. MAO-B inhibitors may differ in adverse events (AEs). However, differences in actual practical clinics are not fully investigated. A retrospective study was conducted using FAERS, the largest database of spontaneous adverse events. AE signals for MAO-B inhibitors, including selegiline, rasagiline, and safinamide, were detected using the reporting odds ratio method and compared. Hypocomplementemia, hepatic cyst, hepatic function abnormal, liver disorder and cholangitis were detected for selegiline as drug-specific signals. The amphetamine effect was not confirmed for any of the three MAO-B inhibitors. The tyramine reaction was detected as an AE signal only for rasagiline. Moreover, the REM sleep behavior disorder was not detected as an AE signal for safinamide, suggesting that non-dopaminergic effects might be beneficial. Considering the differences in AEs for MAO-B inhibitors will assist with the appropriate PD medication.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93232
citation_title	Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system
citation_author	Asano, Hiroto
	Tian, Yu Shi
	Hatabu, Asuka
	Takagi, Tatsuya
	Ueda, Mikiko
	Ikeda, Kenji
citation_publisher	Nature Research
citation_language	英語
citation_date	2023-11-06
citation_journal_title	Scientific Reports
citation_volume	13
citation_issue	1
citation_firstpage	19272
citation_doi	https://doi.org/10.1038/s41598-023-44142-2
citation_public_url	https://hdl.handle.net/11094/93232

Safety comparisons among monoamine oxidase inhibitors against Parkinson’s disease using FDA adverse event reporting system

閲覧可能ファイル

論文情報

論文詳細を表示